SEC Filing | Amicus Therapeutics

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

QUAKER BIO VENTURES LP

(Last)

(First)

(Middle)

C/O QUAKER BIOVENTURES

2929 ARCH STREET, CIRA CENTRE

(Street)

PHILADELPHIA

19104

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/30/2007

3. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS INC [ FOLD ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series C Convertible Preferred Stock	08/16/2005	⁽²⁾	Common Stock	396,825⁽²⁾	0⁽²⁾	D
Series C Convertible Preferred Stock	08/16/2005	⁽²⁾	Common Stock	132,275⁽²⁾	0⁽²⁾	I	Garden State Life Sciences Venture Fund, L.P.⁽¹⁾
Series C Convertible Preferred Stock	04/17/2006	⁽²⁾	Common Stock	396,825⁽²⁾	0⁽²⁾	D
Series C Convertible Preferred Stock	04/17/2006	⁽²⁾	Common Stock	132,275⁽²⁾	0⁽²⁾	I	Garden State Life Sciences Venture Fund, L.P.⁽¹⁾
Series D Convertible Preferred Stock	09/13/2006	⁽²⁾	Common Stock	135,586⁽²⁾	0⁽²⁾	D
Series D Convertible Preferred Stock	09/13/2006	⁽²⁾	Common Stock	45,195⁽²⁾	0⁽²⁾	I	Garden State Life Sciences Venture Fund, L.P.⁽¹⁾
Series D Convertible Preferred Stock	03/09/2007	⁽²⁾	Common Stock	135,586⁽²⁾	0⁽²⁾	D
Series D Convertible Preferred Stock	03/09/2007	⁽²⁾	Common Stock	45,195⁽²⁾	0⁽²⁾	I	Garden State Life Sciences Venture Fund, L.P.⁽¹⁾

Explanation of Responses:

1. These shares are owned by Garden State Life Sciences Venture Fund L.P., which is under common control with Quaker BioVentures, L.P. Quaker BioVentures Capital, L.P. serves as the general partner of Quaker BioVentures, L.P. and Garden State Life Sciences Venture Fund L.P. and is the indirect beneficial owner of these shares. Quaker Bioventures Capital LLC serves as the general partner of Quaker Bioventures Capital, L.P. and is also the indirect beneficial owner of these shares. Quaker BioVentures, L.P. disclaims beneficial ownership of these shares except to the extent of its proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.

2. Each share is convertible and will automatically convert on a 1-for-1 basis into the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock pursuant to an effective registration statement filed with the U.S. Securities and Exchange Commission. These shares have no expiration date.

	QUAKER BIOVENTURES, L.P. By: Quaker BioVentures Capital, L.P., its General Partner, By: Quaker Bioventures Capital LLC, its General Partner, By: /s/ Sherrill Neff	05/30/2007
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.